Evidence map›Paper›PMID 41505697›Full record

Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2026

Upfront Modified FOLFOXIRI Plus Panitumumab for

Veronica Conca, Daniele Rossini, Carlotta Antoniotti, Sara Lonardi, Filippo Pietrantonio, Roberto Moretto, Lorenzo Antonuzzo, Giovanni Randon, Daniele Lavacchi, Carmelo Pozzo and 17 more

Abstract readClinical Trial, Phase IIIRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Veronica ConcaUnit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.ORCID 0000-0001-7713-4005
Daniele RossiniDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.ORCID 0009-0000-3777-8471
Carlotta AntoniottiUnit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.ORCID 0000-0001-6881-3188
Sara LonardiMedical Oncology Unit 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.ORCID 0000-0002-7593-8138
Filippo PietrantonioMedical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.ORCID 0000-0002-8530-8420
Roberto MorettoUnit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
Lorenzo AntonuzzoDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Giovanni RandonMedical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Daniele LavacchiClinical Oncology Unit, Careggi University Hospital, Florence, Italy.
Carmelo PozzoMedical Oncology, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy.ORCID 0000-0003-4004-9098
Federica MarmorinoUnit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.ORCID 0000-0001-7725-3434
Francesca BergamoMedical Oncology Unit 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.ORCID 0000-0002-8795-4653
Emiliano TamburiniOncology and Palliative Care Department, Tricase City Hospital, Tricase, Italy.
Alessandro PassardiDepartment of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori," Meldola, Italy.ORCID 0000-0002-7099-240X
Roberta FazioMedical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.ORCID 0009-0000-6690-2101
Sabina MurgioniMedical Oncology Unit 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.ORCID 0000-0002-4682-9872
Beatrice BorelliUnit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.ORCID 0000-0002-9739-408X
Angela BuonadonnaDepartment of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy.
Marco Maria GermaniUnit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
Vincenzo FormicaMedical Oncology Unit, Department of Systems Medicine, Tor Vergata University Hospital, Rome, Italy.ORCID 0000-0002-5380-3144
Martina CarulloUnit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.ORCID 0000-0003-2846-2517
Roberto BordonaroMedical Oncology Unit, Azienda Ospedaliera di Rilievo Nazionale e Alta Specializzazione (ARNAS), Ospedale Garibaldi, Catania, Italy.ORCID 0000-0001-5005-0880
Giuseppe AprileDepartment of Oncology, San Bortolo General Hospital, Azienda ULSS8 Berica, Vicenza, Italy.
Alberto ZaniboniMedical Oncology Unit, Poliambulanza Foundation, Brescia, Italy.
Gianluca MasiUnit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.ORCID 0000-0001-8329-8989
Luca BoniClinical Epidemiology Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.ORCID 0000-0003-2217-4047
Chiara CremoliniUnit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.ORCID 0000-0002-0520-4841

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report 5-year results of the phase III randomized TRIPLETE study. Eligible patients with

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsColorectal NeoplasmsPanitumumabProto-Oncogene Proteins B-rafAdultAgedCamptothecinFemaleFluorouracilHumansIrinotecanLeucovorinMaleMiddle AgedOrganoplatinum CompoundsProgression-Free SurvivalBRAF protein, humanCamptothecinFluorouracilIrinotecanLeucovorinOrganoplatinum CompoundsPanitumumabProto-Oncogene Proteins B-raf

Identifiers

PMID41505697
PMCPMC12879191

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.